![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MESDC2 |
Gene summary for MESDC2 |
![]() |
Gene information | Species | Human | Gene symbol | MESDC2 | Gene ID | 23184 |
Gene name | mesoderm development LRP chaperone | |
Gene Alias | BOCA | |
Cytomap | 15q25.1 | |
Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | Q14696 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23184 | MESDC2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.89e-27 | 5.06e-01 | 0.294 |
23184 | MESDC2 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.60e-16 | 1.38e+00 | 0.3487 |
23184 | MESDC2 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.09e-06 | 2.46e-01 | 0.281 |
23184 | MESDC2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.56e-16 | 3.47e-01 | 0.3859 |
23184 | MESDC2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.57e-07 | 3.22e-01 | 0.2585 |
23184 | MESDC2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.19e-14 | 2.67e-01 | 0.3005 |
23184 | MESDC2 | AEH-subject1 | Human | Endometrium | AEH | 1.75e-35 | -5.12e-01 | -0.3059 |
23184 | MESDC2 | AEH-subject2 | Human | Endometrium | AEH | 1.83e-30 | -5.12e-01 | -0.2525 |
23184 | MESDC2 | AEH-subject3 | Human | Endometrium | AEH | 1.16e-34 | -5.12e-01 | -0.2576 |
23184 | MESDC2 | AEH-subject4 | Human | Endometrium | AEH | 1.29e-23 | -5.12e-01 | -0.2657 |
23184 | MESDC2 | AEH-subject5 | Human | Endometrium | AEH | 1.16e-34 | -5.12e-01 | -0.2953 |
23184 | MESDC2 | EEC-subject1 | Human | Endometrium | EEC | 7.64e-34 | -5.12e-01 | -0.2682 |
23184 | MESDC2 | EEC-subject2 | Human | Endometrium | EEC | 1.45e-37 | -5.12e-01 | -0.2607 |
23184 | MESDC2 | EEC-subject3 | Human | Endometrium | EEC | 1.75e-35 | -5.12e-01 | -0.2525 |
23184 | MESDC2 | EEC-subject4 | Human | Endometrium | EEC | 4.51e-35 | -5.12e-01 | -0.2571 |
23184 | MESDC2 | EEC-subject5 | Human | Endometrium | EEC | 4.51e-35 | -5.12e-01 | -0.249 |
23184 | MESDC2 | GSM5276934 | Human | Endometrium | EEC | 7.64e-34 | -5.12e-01 | -0.0913 |
23184 | MESDC2 | GSM5276935 | Human | Endometrium | EEC | 6.74e-36 | -5.12e-01 | -0.123 |
23184 | MESDC2 | GSM5276937 | Human | Endometrium | EEC | 1.15e-28 | -5.12e-01 | -0.0897 |
23184 | MESDC2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 5.88e-25 | -5.12e-01 | -0.1869 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MESDC2 | insertion | Frame_Shift_Ins | rs745891632 | c.632dupA | p.Lys212GlufsTer19 | p.K212Efs*19 | Q14696 | protein_coding | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MESDC2 | SNV | Missense_Mutation | c.14G>A | p.Arg5Lys | p.R5K | Q14696 | protein_coding | tolerated_low_confidence(0.75) | benign(0.005) | TCGA-DD-A1EK-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
MESDC2 | SNV | Missense_Mutation | novel | c.235N>A | p.Gly79Arg | p.G79R | Q14696 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-86-8673-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
MESDC2 | SNV | Missense_Mutation | novel | c.575N>A | p.Gly192Asp | p.G192D | Q14696 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
MESDC2 | deletion | Frame_Shift_Del | rs779080640 | c.632delN | p.Lys211ArgfsTer6 | p.K211Rfs*6 | Q14696 | protein_coding | TCGA-B7-A5TI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | eloxatin | CR | ||
MESDC2 | deletion | Frame_Shift_Del | rs779080640 | c.632delN | p.Lys211ArgfsTer6 | p.K211Rfs*6 | Q14696 | protein_coding | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
MESDC2 | deletion | Frame_Shift_Del | rs779080640 | c.632delA | p.Lys211ArgfsTer6 | p.K211Rfs*6 | Q14696 | protein_coding | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MESDC2 | deletion | Frame_Shift_Del | rs779080640 | c.632delN | p.Lys211ArgfsTer6 | p.K211Rfs*6 | Q14696 | protein_coding | TCGA-BR-8591-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
MESDC2 | deletion | Frame_Shift_Del | rs779080640 | c.632delA | p.Lys211ArgfsTer6 | p.K211Rfs*6 | Q14696 | protein_coding | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
MESDC2 | deletion | Frame_Shift_Del | rs779080640 | c.632delA | p.Lys211ArgfsTer6 | p.K211Rfs*6 | Q14696 | protein_coding | TCGA-CD-A4MI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |